Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05509257 · ClinicalTrials.gov registry record · Early Phase 1
Naltrexone Neuroimaging in Teens With Eating Disorders
A Early Phase 1 study of Eating Disorders and Bulimia Nervosa, sponsored by Children's Mercy Hospital Kansas City.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05509257: Recruiting Early Phase 1 study of Eating Disorders and Bulimia Nervosa, sponsored by Children's Mercy Hospital Kansas City.
NCT05509257 is a Early Phase 1 study of Eating Disorders and Bulimia Nervosa that is actively recruiting participants, run by Children's Mercy Hospital Kansas City. The registered enrollment target is 60 participants, below the 321-participant average among 37 other Eating Disorders trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05509257, a Early Phase 1 study of Eating Disorders and Bulimia Nervosa, is actively recruiting participants, sponsored by Children's Mercy Hospital Kansas City.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Using a randomized, placebo-controlled, crossover study, this study will evaluate functional magnetic resonance imaging (fMRI) as a pharmacodynamic biomarker of opioid antagonism in adolescents with eating disorders. The hypothesis is that fMRI will be able to detect acute reward pathway modulation by naltrexone (an opioid antagonist) in pre-defined regions of interest (anterior cingulate cortex, nucleus accumbens, dorsolateral prefrontal cortex).
Primary Outcome
Acute %Blood oxygenation level dependent (BOLD) change placebo vs. naltrexone in pre-defined regions of interest (anterior cingulate cortex, nucleus accumbens, dorsolateral prefrontal cortex)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Naltrexone
Study Locations (1)
Missouri
- Children's Mercy Research Institute - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-09-17 |
| Est. Completion | 2027-06 |
| Phase | Early Phase 1 |
What NCT05509257 shows while recruiting
NCT05509257 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 321-participant average among 37 other Eating Disorders trials with a reported enrollment target (81% lower).
The record links to 5 conditions, with Eating Disorders appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05509257 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT05509257 about?
NCT05509257 is a clinical study titled "Naltrexone Neuroimaging in Teens With Eating Disorders". Using a randomized, placebo-controlled, crossover study, this study will evaluate functional magnetic resonance imaging (fMRI) as a pharmacodynamic biomarker of opioid antagonism in adolescents with eating disorders. The hypothesis is that fMRI will be able to detect acute reward pathway modulation ...
What is the current status of trial NCT05509257?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 60 participants. The study started on 2022-09-17. Estimated completion is 2027-06.
What conditions does trial NCT05509257 study?
This clinical trial studies the following conditions: Eating Disorders, Bulimia Nervosa, Binge Eating, Purging (Eating Disorders), Anorexia Nervosa, Atypical.
What interventions are being tested in trial NCT05509257?
The interventions under investigation include: Placebo (DRUG), Naltrexone (DRUG).
Who is sponsoring clinical trial NCT05509257?
This trial is sponsored by Children's Mercy Hospital Kansas City, which has 184 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05509257 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eating Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05509257's enrollment target sits among peer trials
60 22nd of 37 higher than 13 of 37 other Eating Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Eating Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Facing Eating Disorder Fears for Anorexia Nervosa
RECRUITING · NA
-
Targeting Transdiagnostic Self-regulatory Factors and Eating Disorder Pathology Among Adults With BInge-spectrum Eating disOrders: A mHEALTH Interoceptive Exposure Intervention (the Bio-HEALTH Study)
RECRUITING · NA
-
Targeting Social Function in Anxiety and Eating Disorders
RECRUITING · NA
-
Diabetes Body Project 2
RECRUITING · NA
-
Acceptability and Feasibility of a Single-Session Online Parent-Focused Intervention Targeting Child Body Image Development
RECRUITING · NA
-
Developing an Artificial Intelligence (AI) Chatbot for Adolescents and Young Adults With Eating Disorders
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI